Mavacamten

Unassigned

New Medicines

Obstructive hypertrophic cardiomyopathy

Information

New molecular entity
Sanofi
Sanofi

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

Myosin inhibitor that reduces excessive cardiac muscle contractility
Hypertrophic cardiomyopathy has an estimated adult prevalence of 1 in 500, with left and/or right ventricular hypertrophy. Usually familial (autosomal dominant) [1].
Obstructive hypertrophic cardiomyopathy
Oral